Limitation of Excessive Extracellular Matrix Turnover May Contribute to Survival Benefit of Spironolactone Therapy in Patients With Congestive Heart Failure: Insights From the Randomized Aldactone…

By F. Zannad, F. Alla, B. Dousset, Alfonso T. Perez, B. Pitt. Circulation, 2000

929 citations recorded by the source corpus.

Subfields: Cardiology and Cardiovascular Medicine, Endocrinology, Diabetes and Metabolism

View Paper: https://www.semanticscholar.org/paper/ff3c2b1e62f42bcf1c7e1fdc17982f4792469dbd

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Cardiology and Cardiovascular Medicine

1. A. Takawale
2. B. Maron
3. Douglas P. Zipes
4. Z. Kassiri
5. M. Maron

Citations in the corpus

• Task Force on Sudden Cardiac Death of the European Society of Cardiology. (2001, background): “The reason for the latter effect is unclear, but may include prevention of hypokalaemia and regression of aldosterone-related interstitial fibrosis([137]).”
• Effect of spironolactone on diastolic function and exercise capacity in patients with heart failure with preserved ejection fraction: the Aldo-DHF randomized controlled trial. (2013, neutral): “Isovolumic relaxation time, ms 89 (26) 88 (25) 89 (26)”
• Cardiac fibroblasts, fibrosis and extracellular matrix remodeling in heart disease (2012, background): “In patients with congestive heart failure, high serum levels of cardiac fibrosis (PIIINP and PICP) are significantly associated with poor outcome [101].”